This comprehensive guide provides healthcare professionals with essential information for prescribing Dolutegravir effectively and safely.

Patient Selection:
Dolutegravir is suitable for most HIV-positive patients, including treatment-naive individuals and those switching from other regimens. It can be used in adults, adolescents, and children weighing at least 6 kg.

Dosing Guidelines:
Adults and adolescents (12 years, 40 kg): 50mg once daily
Pediatric patients (6 kg): Weight-based dosing using 10mg dispersible tablets
With certain medications: May require 50mg twice daily

Drug Interactions:
Important interactions to consider include medications that affect gastric pH (antacids, H2 antagonists, PPIs), certain anticonvulsants, rifampin, and supplements containing polyvalent cations. Timing of administration may need adjustment.

Baseline Testing:
Before initiating Dolutegravir, conduct baseline HIV-1 RNA, CD4+ count, resistance testing if available, hepatitis B and C screening, pregnancy test for women of childbearing potential, and renal function assessment.

Monitoring:
Regular monitoring should include viral load at 4 weeks, 12 weeks, and then every 3-6 months, CD4+ count every 3-6 months, assessment of adherence and tolerability, and screening for opportunistic infections.

Special Populations:
Pregnancy: WHO recommends Dolutegravir for pregnant women with appropriate counseling
Renal impairment: No dose adjustment needed
Hepatic impairment: Use with caution in severe impairment

Patient Counseling:
Educate patients about the importance of adherence, potential side effects, drug interactions, and the need for regular monitoring. Emphasize that Dolutegravir is not a cure but effectively controls HIV when taken consistently.